Skip to Content

Rilonacept Regeneron

Previous name: Arcalyst
Active Substance: rilonacept
Common Name: rilonacept
ATC Code: L04AC08
Marketing Authorisation Holder: Regeneron UK Limited
Active Substance: rilonacept
Status: Withdrawn
Authorisation Date: 2009-10-23
Therapeutic Area: Cryopyrin-associated Periodic Syndromes
Pharmacotherapeutic Group: Immunosuppressants

Therapeutic Indication

Rilonacept Regeneron is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) with severe symptoms, including familial cold auto-inflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS), in adults and children aged 12 years and older.

The marketing authorisation for Rilonacept Regeneron has been withdrawn at the request of the marketing-authorisation holder.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.